Journal of International Oncology››2015,Vol. 42››Issue (2): 141-143.doi:10.3760/cma.j.issn.1673-422X.2015.02.016
Previous ArticlesNext Articles
Zhong Jingmin, Zeng Liang
Online:
2015-02-08Published:
2015-02-02Contact:
Zeng Liang E-mail:zlxx03@qq.comZhong Jingmin, Zeng Liang. Metastatic mechanisms of breast cancer[J]. Journal of International Oncology, 2015, 42(2): 141-143.
[1] Wang B, Li J, Sun M,et al. MiRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features[J]. IUBMB Life, 2014, 66(5): 371-377. [2] Lagadec C, Romon R, Tastet C, et al. Ku86 is important for TrkA overexpressioninduced breast cancer cell invasion[J]. Proteomics Clin Appl, 2010, 4(6-7): 580-590. [3] Lee HH, Lim CA, Cheong YT, et al. Comparison of protein expression profiles of different stages of lymphnodes metastasis in breast cancer[J]. Int J Biol Sci, 2012, 8(3): 353-362. [4] Mathias RA, Simpson RJ. Towards understanding epithelialmesenchymal transition:a proteomics perspective[J]. Biochim Biophys Acta, 2009, 1794(9): 1325-1331. [5] Liu J, Chen Y, Shuai S, et al. TRPM8 promotes aggressiveness of breast cancer cells by regulating EMT via activating AKT/GSK3β pathway[J]. Tumour Biol, 2014, 35(9): 8969-8977. [6] Zeng Q, Zhang P, Wu Z, et al. Quantitative proteomics reveals ERα involvement in CD146induced epithelialmesenchymal transition in breast cancer cells[J]. J Proteomics, 2014, 103: 153-169. [7] Foroni C, Broggini M, Generali D, et al. Epithelialmesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact[J]. Cancer Treat Rev, 2012, 38(6): 689697. [8] Descotes F, Jézéquel P, Spyratos F, et al. Identification of potential prognostic biomarkers for nodenegative breast tumours by proteomic analysis: a multicentric 2004 national PHRC study[J]. Int J Oncol, 2012, 41(1): 92-104. [9] Xu SG, Yan PJ, Shao ZM. Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using twodimensional differential gel electrophoresis[J]. J Cancer Res Clin Oncol, 2010, 136(10): 1545-1556. [10] Krawczyk N, MeierStiegen F, Banys M, et al. Expression of stem cell and epithelialmesenchymal transition markers in circulating tumor cells of breast cancer patients[J]. Biomed Res Int, 2014: 415721. [11] Bartkowiak K, Effenberger KE, Harder S, et al. Discovery of a novel unfolded protein response phenotype of cancerstem/progenitorcells from the bonemarrow of breastcancer patients[J]. J Proteome Res, 2010, 9(6): 3158-3168. [12] Rack B, Schindlbeck C, Jückstock J, et al. Circulating tumor cells predict survival in early averagetohigh risk breast cancer patients[J]. J Natl Cancer Inst, 2014, In press. [13] Woodward WA, Krishnamurthy S, Lodhi A, et al. Aldehyde dehydrogenase1 immunohistochemical staining in primary breast cancer cells independently predicted overall survival but did not correlate with thepresence of circulating or disseminated tumors cells[J]. J Cancer, 2014, 5(5): 360-367. [14] Hill JJ, Tremblay TL, Pen A, et al. Identification of vascularbreast tumormarkers by lasercapture microdissection and labelfree LCMS[J]. J Proteome Res, 2011, 10(5): 2479-2493. [15] Semenza GL. Cancerstromal cell interactions mediated by hypoxiainducible factors promote angiogenesis, lymphangiogenesis, and metastasis[J]. Oncogene, 2013, 32(35): 4057-4063. [16] Onishi T, Hayashi N, Theriault RL, et al. Future directions of bonetargeted therapy for metastatic breast cancer[J]. Nat Rev Clin Oncol, 2010, 7(11): 641-651. [17] Ma H, Liang C, Wang G, et al. MicroRNAmediated cancer metastasis regulation via heterotypic signals in the microenvironment[J]. Curr Pharm Biotechnol, 2014, 15(5): 455-458. [18] Hong B, Li H, Zhang M, et al. p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion[J]. Int J Cancer, 2015, 136(1): 34-43. [19] Naba A, Clauser KR, Lamar JM, et al. Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters[J]. Elife, 2014, 3: e01308. [20] Cawthorn TR, Moreno JC, Dharsee M, et al. Proteomic analyses reveal high expression of decorin and endoplasmin (HSP90B1) are associated with breast cancer metastasis and decreased survival[J]. PLoS One, 2012, 7(2): e30992. [21] Jin L, Zhang Y, Li H, et al. Differential secretome analysis reveals CST6 as a suppressor of breast cancer bone metastasis[J]. Cell Res, 2012, 22(9): 1356-1373. [22] Louie E, Chen XF, Coomes A, et al. Neurotrophin3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis[J]. Oncogene, 2013, 32(35): 4064-4077. |
[1] | Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[2] | Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234. |
[3] | Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238. |
[4] | Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174. |
[5] | Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118. |
[6] | Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82. |
[7] | Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer: present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58. |
[8] | Wang Jing, Xu Wenting.Value of NLR, CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526. |
[9] | Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531. |
[10] | Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456. |
[11] | Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462. |
[12] | Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying.Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2023, 50(8): 475-483. |
[13] | Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356. |
[14] | Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367. |
[15] | Yang Lirong, Wang Yufeng.Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer[J]. Journal of International Oncology, 2023, 50(4): 220-226. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||